SMA Neurologists News and Resources
Neurology Info 1
Design settings and even apply custom CSS to this text in the module Advanced settings.
Neurology Info 2
Design settings and even apply custom CSS to this text in the module Advanced settings.
Neurology Info 3
Design settings and even apply custom CSS to this text in the module Advanced settings.
Featured Neurologists Articles on HCP
A Physical Therapist’s Perspective On a Treatment for SMA in Patients 2 Months and Older Sponsored Post
As key team members in the management of spinal muscular atrophy (SMA),1physical therapists need to understand how disease-modifying therapies may impact patients with SMA and how to best assess these patients over time. Evrysdi (risdiplam) is a disease-modifying...
Grant Awarded to Find Affordable Treatments for Children
A researcher from Keele University School of Medicine in the U.K. was awarded a £99,959 ($138,633) research grant to identify and evaluate potential — and more affordable — treatments to improve the health of children with spinal muscular atrophy (SMA). The two-year...
A Physical Therapist’s Perspective On a Treatment for SMA in Patients 2 Months and Older Sponsored Post
As key team members in the management of spinal muscular atrophy (SMA),1physical therapists need to understand how disease-modifying therapies may impact patients with SMA and how to best assess these patients over time. Evrysdi (risdiplam) is a disease-modifying...
Novartis Poised for Phase 3b SMART Study of Zolgensma
Novartis will initiate SMART, a Phase 3b clinical study to evaluate the safety and efficacy of the one-time gene therapy Zolgensma (onasemnogene abeparvovec) in young children with spinal muscular atrophy (SMA) who weigh 8.5 to 21 kilograms (about 18 to 46 pounds). ...
Danish Family Races to Raise $2.4M for Daughter’s Zolgensma Therapy
Ayah Lundt, a 15-month-old Danish girl with spinal muscular atrophy (SMA) type 2, is helping bring the world together as her parents race to raise $2.4 million for a single dose of Zolgensma before she becomes ineligible for the treatment when she turns 2 in January....
#AANAM – Zolgensma May Lead to Faster, Greater Gains Than Spinraza
Zolgensma may result in faster and greater functional improvements than Spinraza (nusinersen) in infants with spinal muscular atrophy (SMA) treated up to 2 years of age, according to a survey of 22 health providers in the U.S. Given the survey’s limitations, such as...
Latest Posts from SMA News Today
Recent SMA Neurologist News
RSS feed from SMA News Today
SMA Forums -- Neurologist
RSS feed from SMA News Today
